Wednesday will go down in history for Codex DNA (NASDAQ: DNAY) . The genetics-focused biotech saw its share price rocket 39% higher, thanks to a potentially very lucrative deal with a deep-pocketed pharmaceutical giant.
Codex DNA disclosed in a regulatory filing that it has entered into a research collaboration and license agreement with U.S. pharmaceutical company Pfizer (NYSE: PFE) , these days best known as the co-developer of the Comirnaty coronavirus vaccine.
Image source: Getty Images.
For further details see:
Why Codex DNA Trounced the Market Today